Welcome to our dedicated page for Johnson & Johnson news (Ticker: JNJ), a resource for investors and traders seeking the latest updates and insights on Johnson & Johnson stock.
Johnson & Johnson reports healthcare developments across its Innovative Medicine and MedTech businesses. News commonly covers clinical and scientific data in immunology, oncology, neurology and neuropsychiatry, including medicines and candidates such as CAPLYTA, TREMFYA, JNJ-4804, seltorexant and the INVEGA long-acting injectable schizophrenia portfolio.
Company updates also include medical technology programs such as the investigational OTTAVA robotic surgical system, product and patient-education initiatives, quarterly sales and earnings releases, dividend actions, investor presentations and governance or investor-relations appointments.
Johnson & Johnson (NYSE: JNJ) announced a collaboration with the WHO and the government of Sierra Leone to administer its Ebola vaccine regimen as part of an early access clinical program. This initiative aims to prevent further Ebola spread in West Africa, especially following a resurgence of cases in Guinea. The vaccine regimen has received WHO Prequalification, enhancing its accessibility in affected regions. The program targets health workers and vulnerable populations, with plans to vaccinate up to 200,000 individuals. Johnson & Johnson aims to bolster global health preparedness against infectious diseases.
Johnson & Johnson (JNJ) announced the resumption of its COVID-19 single-shot vaccine for adults in the U.S. under Emergency Use Authorization (EUA) following CDC and FDA approval. This decision comes after evaluating a rare blood clotting risk. The vaccine demonstrated 66.1% effectiveness against moderate to severe disease in the Phase 3 ENSEMBLE study. The company plans to file for a Biologics License Application later in 2021. Health authorities continue to monitor safety, emphasizing the need for prompt medical attention for specific symptoms. Updated EUA fact sheets are now available.
Johnson & Johnson (NYSE: JNJ) announced on April 20, 2021, that the European Medicines Agency's Pharmacovigilance Risk Assessment Committee confirmed the positive benefit-risk profile of its COVID-19 vaccine. Following the review of rare adverse events, the company will update vaccine information to include guidance on diagnosing and managing these cases. Shipments of the Janssen COVID-19 vaccine will resume in the EU, Norway, and Iceland. The vaccine demonstrated 85% effectiveness in preventing severe disease during the ENSEMBLE Phase 3 trial, with continued monitoring by health authorities.
Johnson & Johnson (NYSE: JNJ) reported strong first-quarter 2021 results, with reported sales reaching $22.32 billion, representing a 7.9% increase from $20.69 billion in 2020. Net earnings rose to $6.20 billion, up 6.9% year-over-year, resulting in an EPS of $2.32. The Pharmaceutical segment led growth with a 9.6% increase, driven by key products like DARZALEX and STELARA. Medical Devices also saw an 8.8% growth, aided by recovery from COVID impacts. However, Consumer Health segment sales declined 2.3% due to prior year comparisons.
Johnson & Johnson (NYSE: JNJ) has announced a 5.0% increase in its quarterly dividend, raising it from $1.01 to $1.06 per share. This marks the 59th consecutive year of dividend increases, reflecting the company's strong financial position and confidence in future growth. The annualized dividend is now $4.24 per share, up from $4.04. The next dividend is payable on June 8, 2021, to shareholders recorded by May 25, 2021, with an ex-dividend date of May 24, 2021.
Johnson & Johnson (NYSE: JNJ) has signed an agreement with the African Vaccine Acquisition Trust (AVAT) to supply up to 400 million doses of its single-shot COVID-19 vaccine to African Union member states. Initial deliveries are set for Q3 2021, pending regulatory approvals. The vaccine has shown a 67% reduction in symptomatic COVID-19 and is 85% effective at preventing severe disease. J&J's vaccine is designed for wide distribution, remaining stable at common refrigeration temperatures, enhancing its accessibility in remote areas.
Johnson & Johnson (NYSE: JNJ) announced that the World Health Organization (WHO) granted Emergency Use Listing (EUL) for its single-shot COVID-19 vaccine. The vaccine shows a 67% reduction in symptomatic COVID-19 and 85% effectiveness against severe cases. This approval is pivotal for global vaccine distribution, particularly through the COVAX Facility, aiming to provide equitable access to lower-income countries. The vaccine's compatibility with standard storage and distribution makes it significant for pandemic response. Previous authorizations include Emergency Use Authorization in the U.S. and conditional approval in the EU.
Johnson & Johnson (NYSE: JNJ) announced that the CDC's Advisory Committee on Immunization Practices has recommended its single-shot COVID-19 vaccine for individuals 18 and older under Emergency Use Authorization (EUA) granted by the FDA. The vaccine, developed by Janssen, aims to enhance the U.S. national immunization program. Johnson & Johnson plans to deliver 100 million doses in the first half of 2021 and will file for a Biologics License Application later this year. The company is committed to making the vaccine available on a not-for-profit basis during the pandemic.
On February 27, 2021, Johnson & Johnson (NYSE: JNJ) announced that the FDA issued Emergency Use Authorization for its single-dose COVID-19 vaccine. The decision is based on Phase 3 ENSEMBLE study data showing 85% effectiveness in preventing severe disease. The company aims to deliver 100 million doses in the U.S. by mid-2021. The vaccine, which has not yet received full FDA approval, utilizes the AdVac® vaccine platform and presents advantages in storage and distribution, aiding in global vaccination efforts.
On Feb. 26, 2021, Johnson & Johnson (NYSE: JNJ) announced that the FDA's VRBPAC recommended Emergency Use Authorization for its single-shot COVID-19 vaccine for adults. The recommendation was based on the Phase 3 ENSEMBLE trial demonstrating safety and efficacy. If authorized, 20 million doses will be available by March, with a goal of 100 million by mid-2021. The vaccine can be stored at standard temperatures, enhancing distribution. The company is also pursuing approvals in Europe and other global markets to combat COVID-19.